Pomalidomide and nivolumab for virus-related cancers
Treatments studied
Part of Cancer, Immune system & allergy, Infections clinical trials.
This trial tests two drugs (pomalidomide and nivolumab) in people with cancers caused by viruses. The goal is to see if this combination can shrink or control tumors that haven't responded to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a virus-linked cancer (like EBV-positive Hodgkin lymphoma or nasopharyngeal cancer, HPV-positive cervical or head and neck cancer, Kaposi sarcoma, or hepatitis-related liver cancer) that has not responded to standard treatment.
- You need to be in generally good health, able to do daily activities, and have adequate organ function (kidneys, liver, blood counts).
- If you are HIV-positive, you must be on HIV medications with a viral load under 400.
- You must not have an autoimmune disease requiring immunosuppressive treatment, or severe heart/lung problems.
- You must be willing to follow strict pregnancy prevention measures if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower, less frequent dose of an immunotherapy drug called nivolumab for people with certain advanced cancers. The goal is to see if a reduced dose can still control cancer while causing fewer side effects.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Hear when a new Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.